Target General Infomation
Target ID
T30938
Former ID
TTDI00934
Target Name
RNA polymerase
Target Type
Successful
Disease HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10: B17.1, B18.2]
Head and neck cancer [ICD9: 140-149, 140-229; ICD10: C07-C14, C32-C33]
Influenza virus [ICD10: J11.1]
Function
DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.
UniProt ID
Drugs and Mode of Action
Drug(s) T-705 Drug Info Registered Influenza virus [547272]
TAS-106 Drug Info Phase 2 Head and neck cancer [522408]
JTK-003 Drug Info Discontinued in Phase 2 HCV infection [547588]
R-1479 Drug Info Discontinued in Phase 1 HCV infection [547741]
XTL-2125 Drug Info Discontinued in Phase 1 HCV infection [536646]
Inhibitor JTK-003 Drug Info [544194]
R-1479 Drug Info [527900]
Modulator T-705 Drug Info
TAS-106 Drug Info
XTL-2125 Drug Info
Pathways
KEGG Pathway Purine metabolism
Pyrimidine metabolism
Metabolic pathways
RNA polymerase
References
Ref 522408ClinicalTrials.gov (NCT00737360) Phase II Study of TAS-106 to Treat Head and Neck Cancer. U.S. National Institutes of Health.
Ref 536646Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19.
Ref 547272Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014667)
Ref 547588Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017555)
Ref 547741Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018944)
Ref 527900The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem. 2006 Feb 17;281(7):3793-9. Epub 2005 Nov 29.
Ref 544194Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses. 2010 April; 2(4): 826-866.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.